Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial results

Novo Nordisk STEP Young trial positive results

Analysis based on 9 articles · First reported Sep 07, 2026 · Last updated Sep 07, 2026

Sentiment
70
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The positive results could expand semaglutide's label to younger children, potentially increasing sales and strengthening Novo Nordisk's position in the obesity market. The news may boost investor sentiment and support the stock price.

Pharmaceuticals Healthcare

Novo Nordisk announced positive results from the STEP Young phase 3 trial evaluating once-weekly semaglutide in children aged 6 to under 12 with obesity. The trial met its primary endpoint, showing superior BMI reduction at week 68 compared with placebo. 40.4% of children treated with semaglutide were no longer classified as having obesity, versus none in the placebo group. Safety and tolerability were consistent with previous trials. The results will be presented at ObesityWeek 2026 in November.

100 Novo Nordisk announced results
stock
As the developer of semaglutide, Novo Nordisk stands to benefit from expanded indications and potential revenue growth.
Importance 100.0 Sentiment 80.0
per
As a researcher commenting on the trial, she provides expert context but has no direct financial stake.
Importance 20.0 Sentiment 0.0
per
As Novo Nordisk's chief scientific officer, he represents the company's perspective on the trial results.
Importance 20.0 Sentiment 0.0
ngo
The society will host the presentation of detailed results at its annual meeting.
Importance 10.0 Sentiment 0.0
govactor
Its growth charts were used to define obesity categories in the trial.
Importance 10.0 Sentiment 0.0
ngo
Cited for obesity prevalence projections, highlighting the public health need.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.